Purchase this article with an account.
S. Schmidt, A. E. Hoeh, K. B. Schaal, F. Schutt, S. Dithmar; Intravitreal Bevacizumab for Choroidal Neovascularisation in Pathological Myopia. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3455.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of intravitreal bevacizumab as treatment for choroidal neovascularisation due to pathological myopia (mCNV).
Consecutive series of 23 patients with primary or recurrent mCNV treated with intravitreal bevacizumab 1.25mg after being thoroughly informed about the off-label character of the treatment. 17 patients received bevacizumab treatment only, 6 patients additional photodynamic therapy at the time of first injection. Best corrected visual acuity (EDTRS), ophthalmic examination and OCT were performed at baseline and at 6-week intervals. Fluorescein-angiography was performed depending on the clinical and OCT-findings. Reinjections were given every 6 weeks if intra- or subretinal fluid persisted.
Pre-injection mean visual acuity was 0.29 (0.52 logMAR±0.21). During a follow up of 17±14 weeks 1.39±0.8 injections were given. One eye received 4 injections, 2 eyes 3 injections, 2 eyes 2 injections and 18 eyes only one injection. Complete resorption of sub- or intraretinal fluid and inactivation of mCNV shown by angiography were achieved in all patients. Visual acuitiy (VA) improved by 2.8±5.3 lines on average. 9 eyes showed a significant improvement of at least 3 lines, 14 eyes remaind stable and none lost more than one line. No intraocular or systemic side effects were observed.
In this so far largest series of patients with mCNV treated with intravitreal bevacizumab, the treatment seems to be effective and safe.
This PDF is available to Subscribers Only